Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Adaptive double-blind placebo-controlled study of LNP023 in primary IgA nephropathy
MOH_2019-10-07_007207Phase 2Completed
- Sponsor
- Novartis
- Start
- Jun 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in IgA nephropathy (IgAN) comparing LNP023 capsules with Placebo capsules (2 arms). Started Jun 2019; status: completed.
02
Drugs
Iptacopan
03
Conditions
IgA nephropathy (IgAN)
Beyond the preview
Go deeper on MOH_2019-10-07_007207.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on MOH_2019-10-07_007207.